Striking difference in antiproliferative activity of ruthenium- and osmium-nitrosyl complexes with azole heterocycles

scientific article

Striking difference in antiproliferative activity of ruthenium- and osmium-nitrosyl complexes with azole heterocycles is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1021/IC400555K
P932PMC publication ID3733131
P698PubMed publication ID23659478
P5875ResearchGate publication ID236673684

P50authorMichael A. JakupecQ38800373
Samuel M. MeierQ39186748
Dominique LuneauQ56418800
Gabriel E BüchelQ57028497
Ghenadie NovitchiQ57394396
P2093author name stringErwann Jeanneau
Vladimir B Arion
Jean-Bernard Tommasino
Constantin Turta
Maria Novak
Olesea Cuzan
Anatolie Gavriluta
P2860cites workA short history of SHELXQ25938995
Similar Biological Activities of Two Isostructural Ruthenium and Osmium ComplexesQ27650404
Nitric oxide and inflammationQ28196548
Development of organometallic ruthenium-arene anticancer drugs that resist hydrolysisQ33260994
[Os(IV)Cl(5)(Hazole)](-) complexes: synthesis, structure, spectroscopic properties, and antiproliferative activityQ33511495
Nitric oxide (NO): an effector of apoptosisQ33771673
Organometallic indolo[3,2-c]quinolines versus indolo[3,2-d]benzazepines: synthesis, structural and spectroscopic characterization, and biological efficacyQ34014638
Inhibition of endothelial cell functions and of angiogenesis by the metastasis inhibitor NAMI-A.Q34123753
Role of nitric oxide in inflammationQ34418998
Ruthenium- and Osmium-Arene Complexes of 2-Substituted Indolo[3,2-c]quinolines: Synthesis, Structure, Spectroscopic Properties, and Antiproliferative ActivityQ34498243
From bench to bedside--preclinical and early clinical development of the anticancer agent indazolium trans-[tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019 or FFC14A).Q34511975
Mechanistic aspects of the reactions of nitric oxide with transition-metal complexesQ34593711
Chemistry of nitric oxide relevant to biologyQ35660847
Ruthenium antimetastatic agentsQ35972635
Nitric oxide, cell signaling and cell deathQ36029955
Metal-based antitumour drugs in the post genomic era.Q36446191
Therapeutic potential of nitric oxide in cancer.Q36528158
Nitric oxide, a double edged sword in cancer biology: searching for therapeutic opportunitiesQ36601025
Metal-Arene Complexes with Indolo[3,2-c]-quinolines: Effects of Ruthenium vs Osmium and Modifications of the Lactam Unit on Intermolecular Interactions, Anticancer Activity, Cell Cycle, and Cellular AccumulationQ36613535
Mechanism elucidation of the cis-trans isomerization of an azole ruthenium-nitrosyl complex and its osmium counterpartQ36904002
Nitric oxide, apoptosis and macrophage polarization during tumor progression.Q37166559
Antiangiogenic properties of selected ruthenium(III) complexes that are nitric oxide scavengers.Q37340375
Design of selective neuronal nitric oxide synthase inhibitors for the prevention and treatment of neurodegenerative diseasesQ37372675
Nitric oxide: a guardian for vascular grafts?Q37887771
Biological activity of ruthenium and osmium arene complexes with modified paullones in human cancer cells.Q39265638
Organometallic 3-(1H-benzimidazol-2-yl)-1H-pyrazolo[3,4-b]pyridines as potential anticancer agentsQ39451837
En route to osmium analogues of KP1019: synthesis, structure, spectroscopic properties and antiproliferative activity of trans-[Os(IV)Cl4(Hazole)2]Q39510416
A new nitrosyl ruthenium complex: synthesis, chemical characterization, in vitro and in vivo antitumor activities and probable mechanism of actionQ39526209
Osmium(II)--versus ruthenium(II)--arene carbohydrate-based anticancer compounds: similarities and differences.Q39684393
Synthesis, structure, spectroscopic properties, and antiproliferative activity in vitro of novel osmium(III) complexes with azole heterocycles.Q39965882
Metal-based paullones as putative CDK inhibitors for antitumor chemotherapyQ40053135
Osmium NAMI-A analogues: synthesis, structural and spectroscopic characterization, and antiproliferative properties.Q40133724
Chloro half-sandwich osmium(II) complexes: influence of chelated N,N-ligands on hydrolysis, guanine binding, and cytotoxicity.Q40144221
KP1019 (FFC14A) from bench to bedside: preclinical and early clinical development--an overview.Q40337165
Gases as biological messengers: nitric oxide and carbon monoxide in the brainQ40701647
Intracellular protein binding patterns of the anticancer ruthenium drugs KP1019 and KP1339.Q42040747
Synthesis and structural, spectroscopic, and electrochemical characterization of new ruthenium dimethyl sulfoxide nitrosylsQ44073581
A Phase I and pharmacological study with imidazolium-trans-DMSO-imidazole-tetrachlororuthenate, a novel ruthenium anticancer agent.Q44918007
Reversible N-N coupling of NO ligands on dinuclear ruthenium complexes and subsequent N2O evolution: relevance to nitric oxide reductase.Q50873870
Endothelium-derived relaxing factor release on activation of NMDA receptors suggests role as intercellular messenger in the brainQ59062956
Osmium(II) and Ruthenium(II) Arene Maltolato Complexes: Rapid Hydrolysis and Nucleobase BindingQ59986441
Biomolecule binding vs. anticancer activity: Reactions of Ru(arene)[(thio)pyr-(id)one] compounds with amino acids and proteinsQ60240425
The Metal−NO Interaction in the Redox Systems [Cl5Os(NO)]n-,n= 1−3, andcis-[(bpy)2ClOs(NO)]2+/+: Calculations, Structural, Electrochemical, and Spectroscopic ResultsQ64169747
Efficacy of new ruthenium complexes against chemically induced autochthonous colorectal carcinoma in ratsQ69690609
Nitric oxide and its role in apoptosisQ77164340
New ruthenium nitrosyl complexes with tris(1-pyrazolyl)methane (tpm) and 2,2'-bipyridine (bpy) coligands. Structure, spectroscopy, and electrophilic and nucleophilic reactivities of bound nitrosylQ79212452
P433issue11
P407language of work or nameEnglishQ1860
P921main subjectosmiumQ751
P304page(s)6273-6285
P577publication date2013-05-09
P1433published inInorganic ChemistryQ902828
P1476titleStriking difference in antiproliferative activity of ruthenium- and osmium-nitrosyl complexes with azole heterocycles
P478volume52

Reverse relations

cites work (P2860)
Q38792102A survey of the mechanisms of action of anticancer transition metal complexes
Q38851401Anticancer Organometallic Osmium(II)-p-cymene Complexes
Q40786041Biological properties of novel ruthenium- and osmium-nitrosyl complexes with azole heterocycles
Q36287265Bis-picolinamide Ruthenium(III) Dihalide Complexes: Dichloride-to-Diiodide Exchange Generates Single trans Isomers with High Potency and Cancer Cell Selectivity
Q37148450Dicopper(II) and dizinc(II) complexes with nonsymmetric dinucleating ligands based on indolo[3,2-c]quinolines: synthesis, structure, cytotoxicity, and intracellular distribution.
Q36026159Functionalized Benzimidazole Scaffolds: Privileged Heterocycle for Drug Design in Therapeutic Medicine.
Q38844730Heteropentanuclear Oxalato-Bridged nd-4f (n=4, 5) Metal Complexes with NO Ligand: Synthesis, Crystal Structures, Aqueous Stability and Antiproliferative Activity
Q60240408Organoruthenium and Osmium Anticancer Complexes Bearing a Maleimide Functional Group: Reactivity to Cysteine, Stability, and Cytotoxicity
Q58117720Osmium-Nitrosyl Oxalato-Bridged Lanthanide-Centered Pentanuclear Complexes - Synthesis, Crystal Structures and Magnetic Properties
Q39022215Ruthenium-nitrosyl complexes with glycine, L-alanine, L-valine, L-proline, D-proline, L-serine, L-threonine, and L-tyrosine: synthesis, X-ray diffraction structures, spectroscopic and electrochemical properties, and antiproliferative activity
Q47743532cis-Tetrachlorido-bis(indazole)osmium(iv) and its osmium(iii) analogues: paving the way towards the cis-isomer of the ruthenium anticancer drugs KP1019 and/or NKP1339.

Search more.